|
|
支气管哮喘治疗药物的研究进展
|
Abstract:
支气管哮喘是全球常见的慢性呼吸道疾病。随着对哮喘有关生理、病理等机制的深入研究，用于治疗该疾病的药物不断被研发出来。现本文对治疗支气管哮喘药物进行概述，从药物种类、作用机制及治疗中出现的不良反应进行总结。
Bronchial asthma is a common chronic respiratory disease worldwide. With the in-depth research on the physiological and pathological mechanisms related to asthma, a variety of different drugs have been developed for the treatment of asthma. This article now provides an overview of the drugs used in the treatment of bronchial asthma, summarizes the types of drugs, their mechanisms of action, and their adverse effects in treatment.
| [1] | 卞如濂. 吸入型糖皮质激素的药理学特性[J]. 中国实用儿科杂志, 2000(7): 440-441. |
| [2] | Kearns, N., Maijers, I., Harper, J., et al. (2020) Inhaled Corticosteroids in Acute Asthma: A Systemic Review and Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice, 8, 605-617.E6.
https://doi.org/10.1016/j.jaip.2019.08.051 |
| [3] | Ora, J., Calzetta, L., Matera, M.G., et al. (2020) Advances with Glucocorticoids in the Treatment of Asthma: State of the Art. Expert Opinion on Pharmacotherapy, 21, 2305-2316. https://doi.org/10.1080/14656566.2020.1807514 |
| [4] | Global Initiative for Asthma (2021) Global Strategy for Asthma Management and Prevention.
https://www.ginasthma.org/ |
| [5] | 陈萍, 赵海涛. β2受体激动剂在支气管哮喘治疗中的合理应用[J]. 中华哮喘杂志(电子版), 2008, 2(3): 220-223. |
| [6] | Nelson, H.S., Weiss S.T., Bleecker E.R., et al. (2006) The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest, 129, 15-26.
https://doi.org/10.1378/chest.129.1.15 |
| [7] | Kobayashi, Y., Mercado, N., Miller-Larsson, A., et al. (2012) In-creased Corticosteroid Sensitivity by a Long Acting β2 Agonist Formoterol via β2 Adrenoceptor Independent Protein Phosphatase 2A Activation. Pulmonary Pharmacology & Therapeutics, 25, 201-207. https://doi.org/10.1016/j.pupt.2012.02.005 |
| [8] | Nwaru, B.I., Ekstr？m, M., Hasvold, P., et al. (2020) Overuse of Short-Acting β2-Agonists in Asthma Is Associated with Increased Risk of Exacerbation and Mortality: A Nationwide Cohort Study of the Global SABINA Programme. European Respiratory Journal, 55, Article ID: 1901872. https://doi.org/10.1183/13993003.01872-2019 |
| [9] | 黄娟, 陈颖, 龙珍, 等. 抗胆碱能药物——噻托溴铵治疗儿童哮喘疗效观察[J]. 中国妇幼保健, 2015, 30(13): 2005-2008. |
| [10] | Cazzola, M., Calzetta, L. and Matera, M.G. (2021) Long-Acting Muscarinic Antagonists and Small Airways in Asthma: Which Link? Allergy, 76, 1990-2001. https://doi.org/10.1111/all.14766 |
| [11] | Cazzola, M., Ora, J., Rogliani, P., et al. (2017) Role of Muscarinic An-tagonists in Asthma Therapy. Expert Review of Respiratory Medicine, 11, 239-253. https://doi.org/10.1080/17476348.2017.1289844 |
| [12] | Kew, K.M. and Dahri, K. (2016) Long-Acting Muscarinic Antagonists (LAMA) Added to Combination Long-Acting Beta2-Agonists and Inhaled Corticosteroids (LABA/ICS) versus LABA/ICS for Adults with Asthma. Cochrane Database of Systematic Reviews, 6, CD011721. https://doi.org/10.1002/14651858.CD011721.pub2 |
| [13] | 江波. 格隆溴铵临床前药效学和药代动力学研究[D]: [博士学位论文]. 杭州: 浙江大学, 2018. |
| [14] | Papi, A., Virchow, J.C., Singh, D., et al. (2021) Extrafine Triple Therapy and Asthma Exacerbation Seasonality: TRIMARAN and TRIGGER post hoc Analyses. Journal of Allergy and Clinical Immunology, 148, 262-265.E2.
https://doi.org/10.1016/j.jaci.2021.01.007 |
| [15] | 郭海英, 周新. 新抗胆碱能药物格隆溴铵[J]. 上海医药, 2013(15): 10-12. |
| [16] | Kirkland, S.W., Vandenberghe, C., Voaklander, B., et al. (2017) Combined Inhaled Beta-Agonist and Anticholinergic Agents for Emergency Management in Adults with Asthma. Cochrane Database of Systematic Reviews, 1, CD001284.
https://doi.org/10.1002/14651858.CD001284.pub2 |
| [17] | 朱珍丽. 抗胆碱能药物在儿童哮喘治疗中的研究进展[J]. 国际儿科学杂志, 2020, 47(8): 561-564. |
| [18] | Barnes, P.J. (2013) Theophylline. American Journal of Respiratory and Critical Care Medicine, 188, 901-906.
https://doi.org/10.1164/rccm.201302-0388PP |
| [19] | 叶伶, 金美玲. 茶碱类药物的研究进展及其临床应用[J]. 世界临床药物, 2009, 30(1): 23-26. |
| [20] | 贺金莲. 茶碱类药治疗哮喘作用评价[J]. 中国医院用药评价与分析, 2008, 8(3): 176-177. |
| [21] | 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版) [J]. 中华结核和呼吸杂志, 2020, 43(12): 1023-1048. |
| [22] | 刘锋, 钟丽球. 孟鲁司特钠药理作用及临床应用研究[J]. 临床合理用药杂志, 2017, 10(12): 83-84. |
| [23] | McGregor, M.C., Krings, J.G., Nair, P., et al. (2019) Role of Biologics in Asthma. American Journal of Respiratory and Critical Care Medicine, 199, 433-445. https://doi.org/10.1164/rccm.201810-1944CI |
| [24] | Manka, L.A. and Wechsler, M.E. (2018) Selecting the Right Biologic for Your Patients with Severe Asthma. Annals of Allergy, Asthma & Immunology, 121, 406-413. https://doi.org/10.1016/j.anai.2018.07.033 |
| [25] | McCracken, J.L., Tripple, J.W. and Calhoun, W.J. (2016) Biologic Therapy in the Management of Asthma. Current Opinion in Allergy & Clinical Immunology, 16, 375-382. https://doi.org/10.1097/ACI.0000000000000284 |
| [26] | Hanania, N.A., et al. (2011) Omalizumab in Severe Allergic Asthma Inadequately Controlled with Standard Therapy: A Randomized Trial. Annals of Internal Medicine, 154, 573-582.
https://doi.org/10.7326/0003-4819-154-9-201105030-00002 |
| [27] | Niven, R.M., Saralaya, D., Chaudhuri, R., et al. (2016) Impact of Omalizumab on Treatment of Severe Allergic Asthma in UK Clinical Practice: A UK Multicentre Observational Study (the APEX II Study). BMJ Open, 6, e11857.
https://doi.org/10.1136/bmjopen-2016-011857 |
| [28] | Pelaia, C., Calabrese, C., Barbuto, S., et al. (2019) Omalizumab Lowers Asthma Exacerbations, Oral Corticosteroid Intake and Blood Eosinophils: Results of a 5-YEAR Single-Centre Observational Study. Pulmonary Pharmacology & Therapeutics, 54, 25-30. https://doi.org/10.1016/j.pupt.2018.11.002 |
| [29] | Agache, I., Beltran, J., Akdis, C., et al. (2020) Efficacy and Safety of Treatment with Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma. A Systematic Review for the EAACI Guidelines—Recommendations on the Use of Biologicals in Severe Asthma. Allergy, 75, 1023-1042.
https://doi.org/10.1111/all.14221 |
| [30] | 李靖. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018, 41(3): 179-185. |
| [31] | Di Bona, D., Fiorino, I., Taurino, M., et al. (2017) Long-Term Real-Life Safety of Omalizumab in Patients with Severe Uncontrolled Asthma: A Nine-Year Study. Respiratory Medicine, 130, 55-60.
https://doi.org/10.1016/j.rmed.2017.07.013 |
| [32] | Hillas, G., Fouka, E. and Papaioannou, A.I. (2020) Antibodies Targeting the Interleukin-5 Signaling Pathway Used as Add-On Therapy for Patients with Severe Eosinophilic Asthma: A Review of the Mechanism of Action, Efficacy, and Safety of the Subcutaneously Administered Agents, Mepolizumab and Benralizumab. Expert Review of Respiratory Medicine, 14, 353-365. https://doi.org/10.1080/17476348.2020.1718495 |
| [33] | Khurana, S., Brusselle, G.G., Bel, E.H., et al. (2019) Long-Term Safety and Clinical Benefit of Mepolizumab in Patients with the Most Severe Eosinophilic Asthma: The COSMEX Study. Clinical Therapeutics, 41, 2041-2056.
https://doi.org/10.1016/j.clinthera.2019.07.007 |
| [34] | Ortega, H.G., Liu, M.C., Pavord, I.D., et al. (2014) Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. The New England Journal of Medicine, 371, 1198-1207. https://doi.org/10.1056/NEJMoa1403290 |
| [35] | Harvey, E.S., Langton, D., Katelaris, C., et al. (2020) Mepolizumab Effectiveness and Identification of Super-Responders in Severe Asthma. The European Respiratory Journal, 55, Article ID: 1902420.
https://doi.org/10.1183/13993003.02420-2019 |
| [36] | Pavord, I.D., Korn, S., Howarth, P., et al. (2012) Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial. The Lancet, 380, 651-659.
https://doi.org/10.1016/S0140-6736(12)60988-X |
| [37] | Chupp, G.L., Bradford, E.S., Albers, F.C., et al. (2017) Efficacy of Mepolizumab Add-On Therapy on Health-Related Quality of Life and Markers of Asthma Control in Severe Eosinophilic Asthma (MUSCA): A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase 3b Trial. The Lancet Respiratory Medicine, 5, 390-400. https://doi.org/10.1016/S2213-2600(17)30125-X |
| [38] | Khatri, S., Moore, W., Gibson, P.G., et al. (2019) Assess-ment of the Long-Term Safety of Mepolizumab and Durability of Clinical Response in Patients with Severe Eosinophilic Asthma. Journal of Allergy and Clinical Immunology, 143, 1742-1751. https://doi.org/10.1016/j.jaci.2018.09.033 |
| [39] | Wechsler, M.E., Hickey, L., Garin, M. et al. (2020) Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma. The Journal of Allergy and Clinical Immunology: In Practice, 8, 3434-3442.
https://doi.org/10.1016/j.jaip.2020.06.009 |
| [40] | Murphy, K., Jacobs, J., Bjermer, L., et al. (2017) Long-Term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. The Journal of Allergy and Clinical Immu-nology: In Practice, 5, 1572-1581.E3.
https://doi.org/10.1016/j.jaip.2017.08.024 |
| [41] | Castro, M., Zangrilli, J., Wechsler, M.E., et al. (2015) Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Counts: Results from Two Multicentre, Parallel, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trials. The Lancet Respiratory Medicine, 3, 355-366. https://doi.org/10.1016/S2213-2600(15)00042-9 |
| [42] | Bjermer, L., Lemiere, C., Maspero, J., et al. (2016) Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest, 150, 789-798.
https://doi.org/10.1016/j.chest.2016.03.032 |
| [43] | Virchow, J.C., Katial, R., Brusselle, G.G., et al. (2020) Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials. The Journal of Allergy and Clinical Immunology: In Practice, 8, 540-548.
https://doi.org/10.1016/j.jaip.2019.07.038 |
| [44] | Pelaia, C., Calabrese, C., Vatrella, A., et al. (2018) Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International, 2018, Article ID: 4839230. https://doi.org/10.1155/2018/4839230 |
| [45] | Harrison, T.W., Chanez, P., Menzella, F., et al. (2021) Onset of Effect and Impact on Health-Related Quality of Life, Exacerbation Rate, Lung Function, and Nasal Polyposis Symptoms for Patients with Severe Eosinophilic Asthma Treated with Benralizumab (ANDHI): A Randomised, Controlled, Phase 3b Trial. The Lancet Respiratory Medicine, 9, 260-274. |
| [46] | Bleecker, E.R., FitzGerald, J.M., Chanez, P., et al. (2016) Efficacy and Safety of Benralizumab for Pa-tients with Severe Asthma Uncontrolled with High-Dosage Inhaled Corticosteroids and Long-Acting β2-Agonists (SIROCCO): A Randomised, Multicentre, Placebo-Controlled Phase 3 Trial. The Lancet, 388, 2115-2127.
https://doi.org/10.1016/S0140-6736(16)31324-1 |
| [47] | Nair, P., Wenzel, S., Rabe, K.F., et al. (2017) Oral Gluco-corticoid—Sparing Effect of Benralizumab in Severe Asthma. The New England Journal of Medicine, 376, 2448-2458. https://doi.org/10.1056/NEJMoa1703501 |
| [48] | Busse, W.W., Bleecker, E.R., FitzGerald, J.M., et al. (2019) Long-Term Safety and Efficacy of Benralizumab in Patients with Severe, Uncontrolled Asthma: 1-Year Results from the BORA Phase 3 Extension Trial. The Lancet Respiratory Medicine, 7, 46-59. |
| [49] | 王艳泓, 邱玉英. 支气管哮喘的生物靶向治疗机制、现状及展望[J]. 中华肺部疾病杂志(电子版), 2019, 12(6): 790-793. |
| [50] | Castro, M., Corren, J., Pavord, I.D., et al. (2018) Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. The New England Journal of Medicine, 378, 2486-2496. https://doi.org/10.1056/NEJMoa1804092 |
| [51] | Rabe, K.F., Nair, P., Brusselle, G., et al. (2018) Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. The New England Journal of Medicine, 378, 2475-2485. https://doi.org/10.1056/NEJMoa1804093 |
| [52] | Corren, J., Castro, M., O’Riordan, T., et al. (2020) Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. The Journal of Allergy and Clinical Immunology: In Practice, 8, 516-526. |
| [53] | Hoy, S.M. (2022) Tezepelumab: First Approval. Drugs, 82, 461-468. https://doi.org/10.1007/s40265-022-01679-2 |
| [54] | Corren, J., Parnes, J.R., Wang, L., et al. (2017) Tezepelumab in Adults with Uncontrolled Asthma. The New England Journal of Medicine, 377, 936-946. https://doi.org/10.1056/NEJMoa1704064 |
| [55] | Menzies-Gow, A., Corren, J., Bourdin, A., et al. (2021) Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. The New England Journal of Medicine, 384, 1800-1809. https://doi.org/10.1056/NEJMoa2034975 |
| [56] | Corren, J., Ambrose, C.S., Salapa, K., et al. (2021) Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy. The Journal of Allergy and Clinical Immunology: In Practice, 9, 4334-4342.E6.
https://doi.org/10.1016/j.jaip.2021.07.045 |
| [57] | Diver, S., Khalfaoui, L., Emson, C., et al. (2021) Effect of Tezepelumab on Airway Inflammatory Cells, Remodelling, and Hyperresponsiveness in Patients with Moder-ate-to-Severe Uncontrolled Asthma (CASCADE): A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. The Lancet Respiratory Medicine, 9, 1299-1312.
https://doi.org/10.1016/S2213-2600(21)00226-5 |
| [58] | Gibson, P.G., Yang, I.A., Upham, J.W., et al. (2017) Effect of Azithromycin on Asthma Exacerbations and Quality of Life in Adults with Persistent Uncontrolled Asthma (AMAZES): A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 390, 659-668. https://doi.org/10.1016/S0140-6736(17)31281-3 |
